Brokers Offer Predictions for Unity Biotechnology, Inc.’s FY2024 Earnings (NASDAQ:UBX)

Unity Biotechnology, Inc. (NASDAQ:UBX) – Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Unity Biotechnology in a note issued to investors on Tuesday, April 16th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($2.42) per share for the year, up from their previous estimate of ($3.83). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.96) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($0.29) EPS.

Unity Biotechnology Trading Down 0.7 %

Shares of NASDAQ:UBX opened at $1.50 on Thursday. The firm has a 50 day moving average of $1.65 and a 200-day moving average of $1.77. The stock has a market capitalization of $25.19 million, a PE ratio of -0.51 and a beta of 0.87. Unity Biotechnology has a 12 month low of $1.50 and a 12 month high of $3.82.

Hedge Funds Weigh In On Unity Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in UBX. Two Sigma Investments LP acquired a new position in Unity Biotechnology during the 1st quarter worth approximately $32,000. Virtu Financial LLC increased its position in Unity Biotechnology by 25.4% during the 2nd quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock worth $35,000 after purchasing an additional 12,681 shares in the last quarter. Jane Street Group LLC acquired a new position in Unity Biotechnology during the 4th quarter worth approximately $37,000. Schonfeld Strategic Advisors LLC acquired a new position in Unity Biotechnology during the 4th quarter worth approximately $38,000. Finally, Commonwealth Equity Services LLC increased its position in Unity Biotechnology by 53.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 24,512 shares of the company’s stock worth $39,000 after purchasing an additional 8,499 shares in the last quarter. 29.49% of the stock is currently owned by institutional investors and hedge funds.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.